Since sublethal doses of Myc B disrupt leading edge protrusions in HER2+ cancer cells, we tested the effects of Myc B on random and directional cell motility, as well as cell invasion through collagen-rich extracellular matrix. This evidence concerns the gene ERBB2 and cancer.